- Millions of Australians currently suffer from poor sleep and anxiety, and the market to fix these issues is expected to be worth US$114 billion (around A$154 billion) by 2025
- The Federal Government has also recognised this is a growing problem, investing more than $5.2 billion into the sector in 2020
- While all mental illnesses require professional treatment, there is a growing industry of complementary medicines
- The medicines aren't designed to treat an illness, but rather the less extreme symptoms that accompany some mental health issues
- The complementary medicine market is already worth $4.2 billion annually and is expected to grow even further as the focus shifts to improving Australians' wellbeing
- Cannabis and its by-products have been a big disruptor of the complementary medicines market, but now a new plant promises to change the market again
- The product is the Noble Kava, which Fiji Kava (FIJ) has spent years perfecting
- Fiji Kava's products are now being sold at Coles, while Blackmores has licensed its medicine for one of its own AnxioCalm products
- Fiji's shares are trading for 24.5 cents on the ASX
Stress, anxiety and poor sleep habits are issues many Australians confront daily, but the market for treating these ailments is growing.
A recent estimate found the sleep aid market would be worth US$114 billion (around A$154 billion) by 2025. In 2018, that market was valued at US$71.04 billion (about A$99.05 billion)
